Monitoring immunoglobulin heavy chain and T-cell receptor gene rearrangement in cfDNA as minimal residual disease detection for patients with acute myeloid leukemia

Oncology Letters
Ling ZhongTao Jiang

Abstract

The present study aimed to examine whether monoclonal immunoglobulin heavy chain (IGH) or T-cell receptor (TCR) gene rearrangement in cell-free DNA (cfDNA) may be used for minimal residual disease (MRD) monitoring in patients with acute myeloid leukemia (AML). Monoclonal IGH and TCR rearrangement in cfDNA were monitored in patients with AML. A total of 94 (40%) patients had monoclonal IGH or TCR rearrangements in cfDNA at diagnosis; 84% of these patients (79 cases) achieved complete remission following 1-3 courses of induction chemotherapy. Among these cases, 89.9% were negative for monoclonal IGH or TCR rearrangement in cfDNA following consolidation chemotherapies. A total of 8 patients with consistently positive monoclonal IGH or TCR rearrangement in cfDNA relapsed within 6-10 months. During follow up, 39 patients demonstrated positive monoclonal IGH or TCR rearrangement in cfDNA and relapsed. Recurrence of monoclonal IGH or TCR rearrangement in cfDNA was observed 1-3 months earlier than bone marrow relapse and 11 patients with solitary extramedullary relapse demonstrated positive monoclonal IGH or TCR rearrangement recurrence in cfDNA. In conclusion, the detection of monoclonal IGH and TCR rearrangement in cfDNA may represen...Continue Reading

References

May 18, 1989·Nature·S Kwok, R Higuchi
Feb 9, 2007·Leukemia·V H J van der VeldenUNKNOWN European Study Group on MRD detection in ALL (ESG-MRD-ALL)
Sep 16, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Daniela CilloniDavid Grimwade
Dec 5, 2012·PloS One·Francesca SalviantiClaudio Orlando
May 17, 2013·Journal of Cancer·Lara MussolinAngelo Rosolen
Sep 26, 2013·International Journal of Molecular Sciences·Yahya I ElshimaliJaydutt V Vadgama
Oct 15, 2013·Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology·Maria Fernanda Setubal Destro RodriguesSuzana Cantanhede Orsini Machado de Sousa
Oct 22, 2013·Cellular & Molecular Immunology·Jing HuangC Cameron Yin
Sep 17, 2015·The New England Journal of Medicine·Hartmut DöhnerClara D Bloomfield
Apr 8, 2017·Leukemia·C S HouriganR B Walter
Oct 25, 2017·Current Hematologic Malignancy Reports·Rahul S Vedula, R Coleman Lindsley

❮ Previous
Next ❯

Citations

May 28, 2020·Frontiers in Cell and Developmental Biology·Jennifer M YoestEric J Duncavage
Dec 29, 2020·Frontiers in Cell and Developmental Biology·Deepshi ThakralSangeeta Vashishtha
May 1, 2021·Cancers·Miho OgawaArinobu Tojo

❮ Previous
Next ❯

Methods Mentioned

BETA
flow cytometry
PCR
electrophoresis
biopsy
flow
density gradient centrifugation

Software Mentioned

VBASE
SPSS

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.